Controversy about the Role of Rifampin in Biofilm Infections: Is It Justified?

Renz, Nora; Trampuz, Andrej; Zimmerli, Werner (2021). Controversy about the Role of Rifampin in Biofilm Infections: Is It Justified? Antibiotics, 10(2) MDPI 10.3390/antibiotics10020165

Preview

Text antibiotics-10-00165.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview

Rifampin is a potent antibiotic against staphylococcal implant-associated infections. In the absence of implants, current data suggest against the use of rifampin combinations. In the past decades, abundant preclinical and clinical evidence has accumulated supporting its role in biofilm-related infections.In the present article, experimental data from animal models of foreign-body infections and clinical trials are reviewed. The risk for emergence of rifampin resistance and multiple drug interactions are emphasized. A recent randomized controlled trial (RCT) showing no beneficial effect of rifampin in patients with acute staphylococcal periprosthetic joint infection treated with prosthesis retention is critically reviewed and data interpreted. Given the existing strong evidence demonstrating the benefit of rifampin, the conduction of an adequately powered RCT with appropriate definitions and interventions would probably not comply with ethical standards.

Interest & Impact

Downloads

39 since deposited on 16 Dec 2021
30 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item